HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Diosmetin

HCID 178730577
New reaction
Print

Completing data — refresh the page later to see the latest

Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
5520-34-3
Standard SMILES
COc1ccc(-c2cc(=O)c3c(O)cc(O)cc3o2)cc1O
InChIKey
MBNGWHIJMBWFHU-UHFFFAOYSA-N
Molecular formula
C16H12O6
Average molar mass
300.26 g/mol

Overview

Diosmetin is a monomethoxyflavone that is the 4'-methyl ether derivative of luteolin. It is a natural product isolated from citrus fruits which exhibits a range of pharmacological activities. It has a role as a tropomyosin-related kinase B receptor agonist, an antioxidant, an antineoplastic agent, a vasodilator agent, an angiogenesis inhibitor, a bone density conservation agent, an anti-inflammatory agent, an apoptosis inducer, a plant metabolite and a cardioprotective agent. It is a monomethoxyflavone, a trihydroxyflavone and a 3'-hydroxyflavonoid. It is functionally related to a luteolin. It is a conjugate acid of a diosmetin-7-olate.

Names & identifiers

Preferred name
Diosmetin
IUPAC
5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chromen-4-one
English name
DIOSMETIN hplc
Molecular formula
C10H10N.Br
Molecular weight
0

Names & synonyms

Diosmetin520-34-3Luteolin 4'-methyl ether4'-MethylluteolinSalinigricoflavonolDiosmetine3',5,7-trihydroxy-4'-methoxyflavone5,7-Dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4H-1-benzopyran-4-one5,7,3'-Trihydroxy-4'-methoxyflavone5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chromen-4-one5,7-Dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4-benzopyrone4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-
Show more names
DIOSMETIN hplc2-Methylquinolizinium bromide
TWZ37241OTDTXSID80199966Flavone, 3',5,7-trihydroxy-4'-methoxy-CHEBI:4630ISAKNOX X202 WHITENING SECRET ESSENCERefChem:34944DTXCID40122457GONGJINHYANG SEOL WHITENING

Database identifiers

CAS
5520-34-3
ChEMBL
CHEMBL90568
ChEBI

Properties

Computed structural propertiesFilling in

XLogP
1.7
Topological polar surface area
96.2 Ų
Hydrogen bond donors
3
Hydrogen bond acceptors
6
Rotatable bonds
2
Heavy atoms
22
Formal charge
0
Complexity
462

Experimental & physicochemical properties

Drugs · 2 items

Pharmaceuticals -> Metabolite of Diosmin

Pharmaceuticals -> Listed in ZINC15

LipidsPolyketides [PK] -> Flavonoids [PK12] -> Flavones and Flavonols [PK1211]
PolymersAntioxidant (polyphenol)
LogP · 3 items

log Kow = 3.10

3.10

3.1

Density1.512 g/cu cm
Color/FormYellow powder
SolubilitySoluble in chloroform, dichloromethane, DMSO, acetone
Endocrine DisruptorsPotential endocrine disrupting compound
Melting Point · 2 items

256-258 °C

228 - 230 °C

Physical Description

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 5 items

This chemical does not meet GHS hazard criteria for 4.8% (2 of 42) of reports.

Warning

H302 (95.2%): Harmful if swallowed [Warning Acute toxicity, oral]

P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 42 reports by companies from 2 notifications to the ECHA C&L Inventory.

Hazard information

Regulatory InformationStatus: Active Update: 13-11-2017 https://echa.europa.eu/registration-dossier/-/registered-dossier/21060
Toxic Combustion ProductsHarmful/toxic vapors, carbon oxides may be released during the fire.
Hazard Classes and CategoriesAcute Tox. 4 (95.2%)

Safety & protection

Fire Fighting Procedures · 2 items

Extinguishing media: Carbon dioxide, dry powder.

Wear an autonomous breathing apparatus and suitable protection clothing against chemical agents.

Storage Conditions · 2 items

Keep container tightly closed in a dry and well-ventilated place. Recommended storage temperature: 2-8 °C

Keep container tightly closed in a dry and well-ventilated place, away from light.

Cleanup Methods · 1 item

Clean-up without creating dust and place in adapted and sealed containers for elimination. Wash the contaminated area with water and soap. Confine washing water and dispose of it complying with the local regulations. After cleaning, quickly eliminate traces of water with a product absorbing liquids (for example: sand, sawdust, universal binder, Kieselguhr).

Chemistry & industry

Pharmacology

Mechanism of Action · 4 items

Various types of tumors are known to overexpress enzymes belonging to the CYP1 family of cytochromes P450. The present study aimed to characterize the metabolism and further antiproliferative activity of the natural flavonoid diosmetin in the CYP1-expressing human hepatoma cell line HepG2. Diosmetin was converted to luteolin in HepG2 cells after 12 and 30 hr of incubation. In the presence of the CYP1A inhibitor alpha-naphthoflavone, the conversion of diosmetin to luteolin was attenuated. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays revealed luteolin to be more cytotoxic than diosmetin. The antiproliferative effect of diosmetin in HepG2 cells was attributed to blockage at the G2/M phase as determined by flow cytometry. Induction of G2/M arrest was accompanied by up-regulation of phospho-extracellular-signal-regulated kinase (p-ERK), phospho-c-jun N-terminal kinase, p53 and p21 proteins. More importantly, induction of G2/M arrest and p53 and p-ERK up-regulation were reversed by the application of the CYP1 inhibitor alpha-naphthoflavone. Taken together, the data provide new evidence on the tumor-suppressing role of cytochrome P450 CYP1A enzymes and extend the hypothesis that the anticancer activity of dietary flavonoids is enhanced by P450-activation.

CYP1A1 and CYP1B1 are two extrahepatic enzymes that have been implicated in carcinogenesis and cancer progression. Selective inhibition of CYP1A1 and CYP1B1 by dietary constituents, notably the class of flavonoids, is a widely accepted paradigm that supports the concept of dietary chemoprevention. In parallel, recent studies have documented the ability of CYP1 enzymes to selectively metabolize dietary flavonoids to conversion products that inhibit cancer cell proliferation. In the present study /the authors/ have examined the inhibition of CYP1A1 and CYP1B1-catalyzed EROD activity by 14 different flavonoids containing methoxy- and hydroxyl-group substitutions as well as the metabolism of the monomethoxylated CYP1-flavonoid inhibitor acacetin and the poly-methoxylated flavone eupatorin-5-methyl ether by recombinant CYP1A1 and CYP1B1. The most potent inhibitors of CYP1-EROD activity were the methoxylated flavones acacetin, diosmetin, eupatorin and the di-hydroxylated flavone chrysin, indicating that the 4'-OCH(3) group at the B ring and the 5,7-dihydroxy motif at the A ring play a prominent role in EROD inhibition. Potent inhibition of CYP1B1 EROD activity was also obtained for the poly-hydroxylated flavonols quercetin and myricetin. HPLC metabolism of acacetin by CYP1A1 and CYP1B1 revealed the formation of the structurally similar flavone apigenin by demethylation at the 4'-position of the B ring, whereas the flavone eupatorin-5-methyl ether was metabolized to an as yet unidentified metabolite assigned E(5)M1. Eupatorin-5-methyl ether demonstrated a submicromolar IC50 in the CYP1-expressing cancer cell line MDA-MB 468, while it was considerably inactive in the normal cell line MCF-10A. Homology modeling in conjunction with molecular docking calculations were employed in an effort to rationalize the activity of these flavonoids based on their CYP1-binding mode. Taken together the data suggest that dietary flavonoids exhibit three distinct modes of action with regard to cancer prevention, based on their hydroxyl and methoxy decoration: (1) inhibitors of CYP1 enzymatic activity, (2) CYP1 substrates and (3) substrates and inhibitors of CYP1 enzymes.

Related reactions

0 records
New reaction record
No related reactions yet

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
CHEBI:4630
UNII
TWZ37241OT
EC Number
208-291-8
Nikkaji
J831A
Solid
Stability/Shelf LifeStable under recommended storage conditions.
Collision Cross Section · 2 items

163.33 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

164.8 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Disposal Methods · 1 item

SRP: Criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.

Preventive Measures · 2 items

Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at the end of workday.

Avoid formation of dust. Avoid contact with skin and eyes. During handling, wear suitable personal protective equipment.

Personal Protective Equipment (PPE) · 2 items

Respiratory protection: For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator. For higher level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges. Use respirators and components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU). Hand protection: Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in accordance with applicable laws and good laboratory practices. Wash and dry hands. Eye protection: Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH (US) or EN 166(EU). Skin and body protection: Complete suit protecting against chemicals, The type of protective equipment must be selected according to the concentration and amount of the dangerous substance at the specific workplace.

Wear imperatively an appropriated mask/respirator, tested and approved by standards such as NIOSH (US) or CEN (EU). ... Handle with protective gloves. The selected gloves have to satisfy the specifications of EU Directive 89/686/EEC and the standard EN 374 derived from it. ... Wear safety glasses. ... Wear suitable protective clothing according to the quantity and the level of activity of the substance at the workplace.

Toxicology

Environmental Fate · 3 items

TERRESTRIAL FATE: Based on a classification scheme(1), an estimated Koc value of 2000(SRC), determined from a structure estimation method(2), indicates that diosmetin is expected to have low mobility in soil(SRC). Volatilization of diosmetin from moist soil surfaces is not expected to be an important fate process(SRC) given an estimated Henry's Law constant of 3.0X10-18 atm-cu m/mole(SRC), using a fragment constant estimation method(2). Diosmetin is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 3.8X10-12 mm Hg at 25 °C(SRC) determined from a fragment constant method(2). Diosmetin does contain chromophores that absorb at wavelengths >290 nm(3) and, therefore, may be susceptible to direct photolysis on soil surfaces exposed to sunlight(SRC).

AQUATIC FATE: Based on a classification scheme(1), an estimated Koc value of 2000(SRC), determined from a structure estimation method(2), indicates that diosmetin is expected to adsorb to suspended solids and sediment(SRC). Volatilization from water surfaces is not expected(3) based upon an estimated Henry's Law constant of 3.0X10-18 atm-cu m/mole(SRC) developed using a fragment constant estimation method(2). Phenols can undergo sensitized photo-oxidation in surface waters exposed to sunlight via reaction with hydroxyl and RO2 radicals with half-lives on the order of days to weeks at the water surface(4); therefore, photo-oxidation may be an important fate process for diosmetin in natural water(SRC). Diosmetin is not expected to undergo hydrolysis in the environment due to the lack of functional groups that hydrolyze under environmental conditions(3). Biodegradation data in water were not available(SRC, 2012).

ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), diosmetin, which has an estimated vapor pressure of 3.8X10-12 mm Hg at 25 °C(SRC), determined from a fragment constant method(2), is expected to exist solely in the particulate phase in the ambient atmosphere. Particulate-phase diosmetin may be removed from the air by wet and dry deposition(SRC).

Food Survey Values · 2 items

Diosmetin is found in citrus fruits and juices, such as orange juice, lemons, grapes and grapefruit(1).

Diosmetin has been extracted from the traditional Chinese herb Galium verum L.(1).

Average Daily Intake · 1 item

Occupational exposure to diosmetin may occur through dermal contact with this compound at workplaces where diosmetin is produced or used. The general population is exposed to diosmetin via ingestion of food, especially citrus fruits and juices, and dermal contact with this compound or other consumer products containing diosmetin. (SRC)

Plant Concentrations · 2 items

Diosmetin has been qualitatively identified in the following plants(1).[Table#8080]

Diosmetin-6,8-di-C-glucoside was detected in Citrus suhuiensis peel, C. medica var 2 peel and C. medica var 2 flesh at concentrations of 4.72, 38 and 301 ug/g dry weight, respectively. Disometin -O-rutinoside was detected in C. hystrix leaf at 106 ng/g dry weight(1).

Soil Adsorption/Mobility · 1 item

Using a structure estimation method based on molecular connectivity indices(1), the Koc of diosmetin can be estimated to be 2000(SRC). According to a classification scheme(2), this estimated Koc value suggests that diosmetin is expected to have low mobility in soil.

Natural Pollution Sources · 1 item

Diosmetin has been identified in the following plants: Capsella bursa-pastoris (Shepherd's Purse plant), Citrus limon (lemon), Mentha spicata (spearmint plant), Origanum vulgare (oregano), Rosmarinus officinalis (rosemary plant), Salvia officinalis (sage), Salvia tomentosa (sage), Tanacetum vulgare (tansy plant), Thymus vulgaris (thyme plant)(1). Diosmetin is found naturally in citrus fruits and juices, such as orange juice, grapes and grapefruit(2).

Human Toxicity Excerpts · 5 items

/ALTERNATIVE and IN VITRO TESTS/ The aim of this study was to assess the effects of diosmetin and hesperetin, two flavonoids present in various medicinal products, on CYP2C8 activity of human liver microsomes using paclitaxel oxidation to 6alpha-hydroxy-paclitaxel as a probe reaction. Diosmetin and hesperetin inhibited 6alpha-hydroxy-paclitaxel production in a concentration-dependent manner, diosmetin being about 16-fold more potent than hesperetin (mean IC50) values 4.25 +/- 0.02 and 68.5 +/- 3.3 uM for diosmetin and hesperetin, respectively). Due to the low inhibitory potency of hesperetin, we characterized the mechanism of diosmetin-induced inhibition only. This flavonoid proved to be a reversible, dead-end, full inhibitor of CYP2C8, its mean inhibition constant (Ki) being 3.13 +/- 0.11 uM. Kinetic analysis showed that diosmetin caused mixed-type inhibition, since it significantly decreased the Vmax (maximum velocity) and increased the Km value (substrate concentration yielding 50% of Vmax) of the reaction. The results of kinetic analyses were consistent with those of molecular docking simulation, which showed that the putative binding site of diosmetin coincided with the CYP2C8 substrate binding site. The demonstration that diosmetin inhibits CYP2C8 at concentrations similar to those observed after in vivo administration (in the low micromolar range) is of potential clinical relevance, since it may cause pharmacokinetic interactions with co-administered drugs metabolized by this CYP.

/ALTERNATIVE and IN VITRO TESTS/ The survival of osteoblasts is one of the determinants of the development of osteoporosis. This study /investigates/ the osteoblastic differentiation induced by diosmetin, a flavonoid derivative, in osteoblastic cell lines MG-63, hFOB, and MC3T3-E1 and bone marrow stroma cell line M2-10B4. Osteoblastic differentiation was determined by assaying alkaline phosphatase (ALP) activity and mineralization degree and measuring various osteoblast-related markers using ELISA. Expression and phosphorylation of Runt-related transcription factor 2 (Runx2), protein kinase Cdelta (PKCdelta), extracellular signal-regulated kinase (ERK), p38, and c-jun-N-terminal kinase (JNK) was assessed by immunoblot. Rac1 activity was determined by immunoprecipitation, and Runx2 activity was assessed by EMSA. Genetic inhibition was performed by small hairpin RNA plasmids or small interfering RNA (siRNA) transfection. Diosmetin exhibited an effect on osteoblastic maturation and differentiation by means of ALP activity, osteocalcin, osteopontin, and type I collagen production, as well as Runx2 upregulation. Induction of differentiation by diosmetin was associated with increased PKCdelta phosphorylation and the activations of Rac1 and p38 and ERK1/2 kinases. Blocking PKCdelta by siRNA inhibition significantly decreased osteoblastic differentiation by inhibiting Rac1 activation and subsequently attenuating the phosphorylation of p38 and ERK1/2. In addition, blocking p38 and ERK1/2 by siRNA transfection also suppressed diosmetin-induced cell differentiation. /This shows/ that diosmetin induced osteoblastic differentiation through the PKCdelta-Rac1-MEK3/6-p38 and PKCdelta-Rac1-MEK1/2- ERK1/2-Runx2 pathways and that it is a promising agent for treating osteoporosis.

Artificial Pollution SourcesDiosmetin's production and use in pharmacological, food and cosmetic research and as an intermediate and ingredient in food supplements and beverages(1) may result in its release to the environment through various waste streams(SRC).
Environmental Bioconcentration · 1 item

An estimated BCF of 13 was calculated in fish for diosmetin(SRC) using a log Kow of 3.10(1) and a regression-derived equation(2). According to a classification scheme(3), this BCF suggests the potential for bioconcentration in aquatic organisms is low(SRC).

Volatilization from Water/Soil · 1 item

The Henry's Law constant for diosmetin is estimated as 3.0X10-18 atm-cu m/mole(SRC) using a fragment constant estimation method(1). This Henry's Law constant indicates that diosmetin is expected to be essentially nonvolatile from water surfaces(2). Diosmetin's Henry's Law constant indicates that volatilization from moist soil surfaces is not expected to occur(SRC). Diosmetin is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 3.8X10-12 mm Hg(SRC) determined from a fragment constant method(1).

Non-Human Toxicity Excerpts · 5 items

/LABORATORY ANIMALS: Subchronic or Prechronic Exposure/ The new natural flavonoid compounds - diosmetin 7-O-beta-L-arabinofuranosyl (1 /to/ 2) beta-D-apiofuranoside (1) and diosmetin 7-O-beta-D-apiofuranoside (2) - were isolated from the acetone extract of date fruits epicarp belonging to family Arecaceae (Palmae). Elucidation of their chemical structures was determined by different spectroscopic methods in addition to the chemical and physical methods of analysis. These compounds were assessed for their biological activity on alloxan diabetic rats. A dose of 1.5 mL of (1) and (2) suspensions/100 gm b. wt were orally administrated to alloxan diabetic rats for 30 days. The treatment of diabetic rats with these compounds resulted in marked improvement of the different biochemical results, i.e. the serum glucose level (highly significant, from 330 + 5.5 mg/dL to 140 + 1.2 mg/dL) treated with (1); liver functions markedly developed both by AST and ALT levels, (reduced significantly from 68.3 + 4.8 u/L to 54 + 5.5 u/L and from 61.0 + 3.6 u/L to 40.1 + 3.6 u/L, respectively) treated with (2), accompanying with mild decrease in both cholesterol and triglycerides levels with (1) or (2). Decrease of TBARS level was observed in whole blood when treated with (1) or (2), while levels of glutathione peroxidase and superoxide dismutase were increased in liver. Serum testosterone level was highly significantly increased (from 705.1 + 3.6 mg/100 mL to 720 + 4.7 mg/100 mL), total acid phosphatase and prostate acid phosphatase activities were highly significantly decreased (from 16.9 + 0.28 u/L to 10.7 + 1.2 u/L and from 9.7 + 0.7 u/L to 6.5 + 1 u/L, respectively) for compound (1).

/LABORATORY ANIMALS: Subchronic or Prechronic Exposure/ Diosmetin (DGVL) extracted from the traditional Chinese herb Galium verum L. has been found to have anticancer activity. In this study, the effects of DGVL on the thymus of U14-bearing mice were investigated. Using flow cytometry, peripheral blood lymphocytes were characterized based on the expression of surface markers for T helper cells (CD4+) and T suppressor cells (CD8+). Serum levels of tumor necrosis factor alpha (TNF-alpha), interleukin-2 (IL-2), IL-10, and transforming growth factor beta1 (TGF-beta1) and a cell proliferation assay were determined with an enzyme-linked immunosorbent assay. The expression of Fas and Fas ligand (FasL) on the thymus was determined by Western blotting. /The/ results showed that DGVL inhibited tumor growth and significantly increased the thymus weight compared with the control. Also, DGVL elevated serum levels of IL-2 and significantly reduced levels of TNF-alpha, TGF-beta1, and IL-10 in a dose-dependent manner. Histological study and terminal dUTP nick end labeling staining results showed that DGVL protected thymus tissue against the onslaught of tumor growth by inhibiting thymus lymphocyte apoptosis. The cell proliferation assay revealed that DGVL might promote more thymus lymphocytes towards proliferation. Furthermore, the ratio of CD4+/CD8+ T lymphocytes was significantly increased from 0.69 to 2.29 by treatment with DGVL. Immunoblotting analyses revealed that the expression of Fas and FasL on the thymus was lower in mice in the DGVL treatment group than in the control mice. In conclusion, DGVL can inhibit tumor growth and protect tumor-induced apoptosis of the thymus, and the mechanism is closely associated with reduced cell death in the thymus and a Fas-FasL-dependent pathway.

Environmental Abiotic Degradation · 1 item

The rate constant for the vapor-phase reaction of diosmetin with photochemically-produced hydroxyl radicals has been estimated as 2.3X10-10 cu cm/molecule-sec at 25 °C(SRC) using a structure estimation method(1). This corresponds to an atmospheric half-life of about 3 hours at an atmospheric concentration of 5X10+5 hydroxyl radicals per cu cm(1). Diosmetin is not expected to undergo hydrolysis in the environment due to the lack of functional groups that hydrolyze under environmental conditions(2). Diosmetin does contain chromophores that absorb at wavelengths >290 nm(2) and, therefore, may be susceptible to direct photolysis by sunlight(SRC). Phenols can undergo sensitized photo-oxidation in surface waters exposed to sunlight via reaction with hydroxyl and RO2 radicals with half-lives on the order of days to weeks at the water surface(3); therefore, photo-oxidation may be an important fate process for diosmetin in natural water(SRC).

The binding mechanism of molecular interaction between diosmetin and human serum albumin (HSA) in a pH 7.4 phosphate buffer was studied using atomic force microscopy (AFM) and various spectroscopic techniques including fluorescence, resonance light scattering (RLS), UV-vis absorption, circular dichroism (CD), and Fourier transform infrared (FT-IR) spectroscopy. Fluorescence data revealed that the fluorescence quenching of HSA by diosmetin was a static quenching procedure. The binding constants and number of binding sites were evaluated at different temperatures. The RLS spectra and AFM images showed that the dimension of the individual HSA molecules were larger after interaction with diosmetin. The thermodynamic parameters, /changes in enthalpy and entropy/ were calculated to be -24.56 kJ/mol and 14.67 J/mol/K, respectively, suggesting that the binding of diosmtin to HSA was driven mainly by hydrophobic interactions and hydrogen bonds. The displacement studies and denaturation experiments in the presence of urea indicated site I as the main binding site for diosmetin on HSA. The binding distance between diosmetin and HSA was determined to be 3.54 nm based on the Forster theory. Analysis of CD and FT-IR spectra demonstrated that HSA conformation was slightly altered in the presence of diosmetin.

The survival of osteoblasts is one of the determinants of the development of osteoporosis. This study /investigates/ the osteoblastic differentiation induced by diosmetin, a flavonoid derivative, in osteoblastic cell lines MG-63, hFOB, and MC3T3-E1 and bone marrow stroma cell line M2-10B4. Osteoblastic differentiation was determined by assaying alkaline phosphatase (ALP) activity and mineralization degree and measuring various osteoblast-related markers using ELISA. Expression and phosphorylation of Runt-related transcription factor 2 (Runx2), protein kinase Cdelta (PKCdelta), extracellular signal-regulated kinase (ERK), p38, and c-jun-N-terminal kinase (JNK) was assessed by immunoblot. Rac1 activity was determined by immunoprecipitation, and Runx2 activity was assessed by EMSA. Genetic inhibition was performed by small hairpin RNA plasmids or small interfering RNA (siRNA) transfection. Diosmetin exhibited an effect on osteoblastic maturation and differentiation by means of ALP activity, osteocalcin, osteopontin, and type I collagen production, as well as Runx2 upregulation. Induction of differentiation by diosmetin was associated with increased PKCdelta phosphorylation and the activations of Rac1 and p38 and ERK1/2 kinases. Blocking PKCdelta by siRNA inhibition significantly decreased osteoblastic differentiation by inhibiting Rac1 activation and subsequently attenuating the phosphorylation of p38 and ERK1/2. In addition, blocking p38 and ERK1/2 by siRNA transfection also suppressed diosmetin-induced cell differentiation. /This shows/ that diosmetin induced osteoblastic differentiation through the PKCdelta-Rac1-MEK3/6-p38 and PKCdelta-Rac1-MEK1/2- ERK1/2-Runx2 pathways and that it is a promising agent for treating osteoporosis.

Metabolism/Metabolites · 5 items

... Diosmetin was metabolised to the structurally similar flavone luteolin in MDA-MB 468 cells, whereas no metabolism was seen in MCF-10A cells...

Various types of tumors are known to overexpress enzymes belonging to the CYP1 family of cytochromes P450. The present study aimed to characterize the metabolism and further antiproliferative activity of the natural flavonoid diosmetin in the CYP1-expressing human hepatoma cell line HepG2. Diosmetin was converted to luteolin in HepG2 cells after 12 and 30 hr of incubation. In the presence of the CYP1A inhibitor alpha-naphthoflavone, the conversion of diosmetin to luteolin was attenuated. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays revealed luteolin to be more cytotoxic than diosmetin. The antiproliferative effect of diosmetin in HepG2 cells was attributed to blockage at the G2/M phase as determined by flow cytometry. Induction of G2/M arrest was accompanied by up-regulation of phospho-extracellular-signal-regulated kinase (p-ERK), phospho-c-jun N-terminal kinase, p53 and p21 proteins. More importantly, induction of G2/M arrest and p53 and p-ERK up-regulation were reversed by the application of the CYP1 inhibitor alpha-naphthoflavone. Taken together, the data provide new evidence on the tumor-suppressing role of cytochrome P450 CYP1A enzymes and extend the hypothesis that the anticancer activity of dietary flavonoids is enhanced by P450-activation.

CYP1A1 and CYP1B1 are two extrahepatic enzymes that have been implicated in carcinogenesis and cancer progression. Selective inhibition of CYP1A1 and CYP1B1 by dietary constituents, notably the class of flavonoids, is a widely accepted paradigm that supports the concept of dietary chemoprevention. In parallel, recent studies have documented the ability of CYP1 enzymes to selectively metabolize dietary flavonoids to conversion products that inhibit cancer cell proliferation. In the present study /the authors/ have examined the inhibition of CYP1A1 and CYP1B1-catalyzed EROD activity by 14 different flavonoids containing methoxy- and hydroxyl-group substitutions as well as the metabolism of the monomethoxylated CYP1-flavonoid inhibitor acacetin and the poly-methoxylated flavone eupatorin-5-methyl ether by recombinant CYP1A1 and CYP1B1. The most potent inhibitors of CYP1-EROD activity were the methoxylated flavones acacetin, diosmetin, eupatorin and the di-hydroxylated flavone chrysin, indicating that the 4'-OCH(3) group at the B ring and the 5,7-dihydroxy motif at the A ring play a prominent role in EROD inhibition. Potent inhibition of CYP1B1 EROD activity was also obtained for the poly-hydroxylated flavonols quercetin and myricetin. HPLC metabolism of acacetin by CYP1A1 and CYP1B1 revealed the formation of the structurally similar flavone apigenin by demethylation at the 4'-position of the B ring, whereas the flavone eupatorin-5-methyl ether was metabolized to an as yet unidentified metabolite assigned E(5)M1. Eupatorin-5-methyl ether demonstrated a submicromolar IC50 in the CYP1-expressing cancer cell line MDA-MB 468, while it was considerably inactive in the normal cell line MCF-10A. Homology modeling in conjunction with molecular docking calculations were employed in an effort to rationalize the activity of these flavonoids based on their CYP1-binding mode. Taken together the data suggest that dietary flavonoids exhibit three distinct modes of action with regard to cancer prevention, based on their hydroxyl and methoxy decoration: (1) inhibitors of CYP1 enzymatic activity, (2) CYP1 substrates and (3) substrates and inhibitors of CYP1 enzymes.

Flos Chrysanthemi (the flower of Chrysanthemum morifolium Ramat.) is widely used in China as a food and traditional Chinese medicine for many diseases. Luteolin and apigenin are two main bioactive components in Flos Chrysanthemi, and chrysoeriol and diosmetin are two methylated metabolites of luteolin in vivo by cathechol-O-methyltransferase (COMT). However, there was /a/ lack of pharmacokinetic information of chrysoeriol and diosmetin after oral administration of Flos Chrysanthemi extract (FCE). The present study aimed to develop an HPLC-UV method for simultaneous determination of rat plasma concentration of luteolin, apigenin, chrysoeriol and diosmetin and utilize it in pharmacokinetic study of the four compounds after orally giving FCE to rats. The method was successfully validated and applied to the pharmacokinetic study when oral administration of FCE to rats with or without co-giving a COMT inhibitor, entacapone. Chrysoeriol and diosmetin were detected in rat plasma after oral administration of FCE and their concentrations were significantly decreased after co-giving entacapone... In conclusion, a sensitive, accurate and reproducible HPLC-UV method for simultaneous determination of luteolin, apigenin, chrysoeriol and diosmetin in rat plasma were developed, pharmacokinetics of chrysoeriol and diosmetin combined with luteolin and apigenin were characterized after oral administration of FCE to rats, which gave us more information on pharmacokinetics and potential pharmacological effects of FCE in vivo.

Diosmetin has known human metabolites that include (2S,3S,4S,5R)-3,4,5-Trihydroxy-6-[5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-4-oxochromen-7-yl]oxyoxane-2-carboxylic acid.

Absorption, Distribution and ExcretionDiosmin is hydrolyzed to its aglycone diosmetin by intestinal microflora enzymes before its absorption into the body.
Cellular LocationsMembrane

Uses & manufacturing

Uses · 3 items

Has use in reference standards, pharmacological research, food research, cosmetic research, synthetic precursor compounds, intermediates and fine chemicals, and as an ingredient in food supplements and beverages

Pharmacology use as a natural flavonoid that can inhibit the activity of human CYP1A enzyme have antimutagenic and anti-allergic characters

Aldose-Reductase-Inhibitor; Antimutagenic; Antirhinoviral; Antiviral; Cancer-Preventative

Methods of ManufacturingPrepared from diosmin isolated from various plants sources.
General Manufacturing InformationDiosmetin is available in food supplements containing citrus bioflavonoids

/ALTERNATIVE and IN VITRO TESTS/ Flavonoids constitute a large class of polyphenolic compounds with cancer preventative properties. /This study/ examined the ability of the natural flavone diosmetin to inhibit proliferation of breast adenocarcinoma MDA-MB 468 and normal breast MCF-10A cells and found that this compound is selective for the cancer cells with slight toxicity in the normal breast cells... Diosmetin caused G1 arrest at 10 uM in MDA-MB 468 cells after 48 hr treatment whereas this effect was not observed in MCF-10A cells. /Data/ suggest that diosmetin exerts cytostatic effects in MDA-MB 468 cells, due to CYP1A1 and CYP1B1 catalyzed conversion to the flavone luteolin.

/ALTERNATIVE and IN VITRO TESTS/ The aim of this study was to assess the effects of diosmetin and hesperetin, two flavonoids present in various medicinal products, on CYP2C8 activity of human liver microsomes using paclitaxel oxidation to 6alpha-hydroxy-paclitaxel as a probe reaction. Diosmetin and hesperetin inhibited 6alpha-hydroxy-paclitaxel production in a concentration-dependent manner, diosmetin being about 16-fold more potent than hesperetin (mean IC50) values 4.25 +/- 0.02 and 68.5 +/- 3.3 uM for diosmetin and hesperetin, respectively). Due to the low inhibitory potency of hesperetin, /investigators/ characterized the mechanism of diosmetin-induced inhibition only. This flavonoid proved to be a reversible, dead-end, full inhibitor of CYP2C8, its mean inhibition constant (Ki) being 3.13 +/- 0.11 uM. Kinetic analysis showed that diosmetin caused mixed-type inhibition, since it significantly decreased the maximum velocity/(Vmax)/and increased /the/ substrate concentration yielding 50% of Vmax (Km) of the reaction. The results of kinetic analyses were consistent with those of molecular docking simulation, which showed that the putative binding site of diosmetin coincided with the CYP2C8 substrate binding site. The demonstration that diosmetin inhibits CYP2C8 at concentrations similar to those observed after in vivo administration (in the low micromolar range) is of potential clinical relevance, since it may cause pharmacokinetic interactions with co-administered drugs metabolized by this CYP.

For more Human Toxicity Excerpts (Complete) data for Diosmetin (7 total), please visit the HSDB record page.

/ALTERNATIVE and IN VITRO TESTS/ The structure-activity relationships of flavonoids with regard to their inhibitory effects on phosphodiesterase (PDE) isozymes are little known. The activities of PDE1-5 were measured by a two-step procedure using cAMP with [(3)H]-cAMP or cGMP with [(3)H]-cGMP as substrates. In the present results, PDE1, 5, 2, and 4 isozymes were partially purified from guinea pig lungs in that order, and PDE3 was from the heart... Diosmetin more-selectively inhibited PDE2 (IC50) of 4.8 uM) than PDE1, PDE4, or PDE5... In conclusion, it is possible to synthesize useful drugs through elucidating the structure-activity relationships of flavonoids with respect to inhibition of PDE isozymes at concentrations used in this in vitro study.

/ALTERNATIVE and IN VITRO TESTS/ This study/ evaluated the effects of increasing concentrations of the flavonoids salvigenin, diosmetin and luteolin on the in vitro metabolism of midazolam (MDZ), a probe substrate for cytochrome P450 (CYP) 3A enzymes, which is converted into 1'-hydroxy-midazolam (1'-OH-MDZ) and 4-hydroxy-midazolam (4-OH-MDZ) by human liver microsomes. Salvigenin had only a modest effect on MDZ metabolism, whereas diosmetin and luteolin inhibited in a concentration-dependent manner the formation of both 1'-OH-MDZ and 4-OH-MDZ, with apparent K(i) values in the 30-50 umol range. Both diosmetin and luteolin decreased 1'-OH-MDZ formation by human recombinant CYP3A4, but not CYP3A5, whereas they decreased 4-OH-MDZ formation by both recombinant enzymes. To assess whether any relationship exists between the physico-chemical characteristics of flavones and their effects on MDZ metabolism, /this study/ tested the effects of three other flavones (flavone, tangeretin, chrysin) on MDZ metabolism by human liver microsomes. Whereas flavones possessing more than two hydroxyl groups (luteolin, diosmetin) inhibited MDZ biotransformation, flavones lacking hydroxyl groups in their A and B rings (flavone, tangeretin) stimulated MDZ metabolism. /This study/ also found close relationships between the maximum stimulatory or inhibitory effects of flavones on 1'-OH-MDZ and 4-OH-MDZ formation rates and their log of octanol/water partition coefficients (logP) or their total number of hydroxyl groups. The results of the study may be of clinical relevance since they suggest that luteolin and diosmetin may cause pharmacokinetic interactions with co-administered drugs metabolized via CYP3A.

For more Non-Human Toxicity Excerpts (Complete) data for Diosmetin (6 total), please visit the HSDB record page.